Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
JONATHAN SLONIN Insider Profile
4 Followers
JONATHAN SLONIN, CMO at Pacira Pharmaceuticals, holds 94.31K shares in Pacira Pharmaceuticals (Ticker: PCRX).
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+31.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of JONATHAN SLONIN's holdings
Insider Roles
CMO
Roles that JONATHAN SLONIN holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jun 08, 2022 - Jun 08, 2023
Return:+37.60%
The most profitable trade made by JONATHAN SLONIN
JONATHAN SLONIN's Trading History
List of latest transactions for each holding click on a transaction to see JONATHAN SLONIN's performance on stock
You May Also Like
JONATHAN SLONIN insider profile FAQ
What is the percentage of profitable transactions made by JONATHAN SLONIN?
The percentage of profitable transactions made by JONATHAN SLONIN is 100%.
What is the average return per transaction made by JONATHAN SLONIN?
The average return per transaction made by JONATHAN SLONIN is 31.40%.
What stocks does JONATHAN SLONIN hold?
JONATHAN SLONIN holds: PCRX stocks.
What was JONATHAN SLONIN’s latest transaction?
JONATHAN SLONIN latest transaction was an Uninformative Sell of $18.95K.
What was JONATHAN SLONIN's most profitable transaction?
JONATHAN SLONIN’s most profitable transaction was an Informative Sell of PCRX stock on June 8, 2022. The return on the trade was 37.60%.
What is JONATHAN SLONIN's role in Pacira Pharmaceuticals?
JONATHAN SLONIN's role in Pacira Pharmaceuticals is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.